These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18940185)

  • 21. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
    Huan Y; Jiang Q; Liu JL; Shen ZF
    J Pharmacol Toxicol Methods; 2015; 71():8-12. PubMed ID: 25464020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
    Wang X; Zhang D; Xu W; Liu H; Wang W
    Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
    Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
    Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity.
    Wang Y; Landheer S; van Gilst WH; van Amerongen A; Hammes HP; Henning RH; Deelman LE; Buikema H
    PLoS One; 2012; 7(10):e46781. PubMed ID: 23071636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
    He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
    Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV. Hemorphins N-terminus sequence influence on the interaction between hemorphins and DPPIV.
    Cohen M; Fruitier-Arnaudin I; Piot JM
    Biochimie; 2004 Jan; 86(1):31-7. PubMed ID: 14987798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum.
    Buckley SJ; Collins PJ; O'Connor BF
    Int J Biochem Cell Biol; 2004 Jul; 36(7):1281-96. PubMed ID: 15109572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors.
    Betancort JM; Winn DT; Liu R; Xu Q; Liu J; Liao W; Chen SH; Carney D; Hanway D; Schmeits J; Li X; Gordon E; Campbell DA
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4437-40. PubMed ID: 19482472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
    Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
    Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of lung metastases by the CD26/DPP4 inhibitor Vildagliptin in mice.
    Jang JH; Baerts L; Waumans Y; De Meester I; Yamada Y; Limani P; Gil-Bazo I; Weder W; Jungraithmayr W
    Clin Exp Metastasis; 2015 Oct; 32(7):677-87. PubMed ID: 26233333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
    Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
    Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes.
    Coumar MS; Chang CN; Chen CT; Chen X; Chien CH; Tsai TY; Cheng JH; Wu HY; Han CH; Wu SH; Huang YW; Hsu T; Hsu LJ; Chao YS; Hsieh HP; Jiaang WT
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1274-9. PubMed ID: 17194587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors.
    Sakashita H; Akahoshi F; Kitajima H; Tsutsumiuchi R; Hayashi Y
    Bioorg Med Chem; 2006 Jun; 14(11):3662-71. PubMed ID: 16460948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form.
    Brandt I; Lambeir AM; Ketelslegers JM; Vanderheyden M; Scharpé S; De Meester I
    Clin Chem; 2006 Jan; 52(1):82-7. PubMed ID: 16254193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs.
    Hjøllund KR; Deacon CF; Holst JJ
    Diabetologia; 2011 Aug; 54(8):2206-8. PubMed ID: 21604085
    [No Abstract]   [Full Text] [Related]  

  • 37. Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues.
    Diez-Torrubia A; Balzarini J; Andrei G; Snoeck R; De Meester I; Camarasa MJ; Velázquez S
    J Med Chem; 2011 Mar; 54(6):1927-42. PubMed ID: 21332170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis.
    Baerts L; Glorie L; Maho W; Eelen A; Verhulst A; D'Haese P; Covaci A; De Meester I
    Pharmacol Res; 2015 Oct; 100():336-40. PubMed ID: 26342756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.
    Greene RJ; Tu H; Gibbs JP; Greg Slatter J
    Xenobiotica; 2011 Nov; 41(11):945-57. PubMed ID: 21867423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.
    Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Hatayama A; Yamamoto S; Kishikawa K; Nakai H; Toda M
    Bioorg Med Chem; 2008 Feb; 16(4):1613-31. PubMed ID: 18039579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.